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Materials Used 
Fmoc protected peptides were purchased from Synbiosci. CLEAR-Amide Resin and 
TentaGel R NH2 were purchased from Peptides International. Goat anti-hemoglobin a stock 
solution of 200 �g/mL and rabbit anti-goat IgG with AP conjugated stock solution of 400 �g/mL 
were purchased from Santa Cruz Biotech. A stock solution of 1 8 .75 mg/mL nitro blue tetrazolium 
chloride (NBT) and 9.4 mg/mL 5-bromo-4-chloro-3-indolyl-phosphate toluidine-salt in 67% 
DMSO was purchased from Roche Diagnostics. N,N-dimethylformamide was purchased from 
Aapptec. Morpholine at over 99% purity, triethylamine at over 99.5% purity, human ferrous 
hemoglobin S, sodium chloride at over 99% purity, tris(hydroxymethyl)aminomethane at over 
99.8% purity, glycine at over 99% purity, sodium dodecyl sulfate at 98% purity, Tween-80 from 
Sigman-Aldrich, and trifluoroacetic acid at over 99% purity was purchased from Sigma-Aldrich. 
Triisopropylsilane at 98% purity from Acros Organics was used. A Ph.D.-7 Phage Display 
Peptide Library Kit containing E. coli K12 ER2738 and Ph.D.-7 Phage Display Peptide Library 
was used to conduct the phage display experiment. 
List of Abbreviations in the Report 
AP: Alkaline phosphate buffer ( 100 mM NaCI, 100 mM Tris-CI at pH 9.5, 50 mM MgCh) 
BCIP: 5-bromo-4-chloro-3-indolyl-phosphate 
ELISA: Enzyme linked immunosorbent assay 
Fmoc: Fluorenylmethyloxycarbonyl chloride 
Hb S: Sickle cell hemoglobin 
HBTU: N,N,N',N'-Tetramethyl-O-(1H-benzotriazol- 1 -yl)uronium hexafluorophosphate 
HOBt: Hydroxybenzotriazole 
NBT: Nitro blue tetrazolium chloride 
PBS: Phosphate buffered saline (137 mM NaCI, 2.7 mM KCI, 1 0  mM Na2HP04, and 2 mM 
KH2P04 ) 
PBST: PBS with 0 . 1  % Tween-80 
SPPS: Solid phase peptide synthesis 
TBS: Tris buffered saline ( 10  mM Tris at pH 8, 1 50 mM NaCl) 
TBST: TBS with 0. 1 % Tween-80 
TEA: Triethylamine 
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Abstract 
Sickle cell disease is a genetic disorder that affects the hemoglobin within red blood cells. 
A point mutation in the gene coding for the �-subunit of hemoglobin allows the mutant chain to 
interact with a hydrophobic pocket of another hemoglobin in a deoxygenated environment, 
causing polymerization of the proteins. This creates the characteristic sickle-shape of the 
diseased blood cells that can clog capillaries, leading to tissue damage and cell death. Currently, 
there are limited options for those affected with sickle cell disease. The research to be presented 
is focused on discovering peptides that can interact with the mutated hemoglobin and prevent 
aggregation. A novel proline-rich peptide ligand, ZSF39, was identified through a phage display 
against deoxygenated sickle cell hemoglobin. A combinatorial peptide library based on the 
structure of ZSF39 was synthesized and screened for binding affinity using an ELISA. A tightly 
binding peptide, LHSl, was discovered through the ELISA and found to have a significant 
inhibitory effect on the polymerization of sickle cell hemoglobin. This work represents a novel 
approach for the discovery of therapeutics for this debilitating disorder. 
Chapter I: Sickle Cell Disease 
A. Sickle Cell Disease Overview 
Sickle cell disease, one of the most common monogenic disorders, is an inherited blood 
disease. It encompasses a variety of disorders that all result in the polymerization of hemoglobin, 
the majority of which are due to the sickle cell hemoglobin mutation Hb SS. The disorder was 
first described by Herrick in 1 9 1 0, and the connection with a hemoglobin abnormality was first 
suggested by Linus Pauling in 1945.1 Today, there are more than 280,00 children born 
worldwide with sickle cell disease annually.2 Although the disease affects many people every 
year, it is characterized as a rare disease in the United States because the majority of the people 
affected are in sub-Saharan areas of Africa. This disease causes significant mortality, with a 
median survival age of 42 years for men and 48 years for women in the United States,3 and also 
causes a variety of symptoms that impact the lives of patients. Although this disease affects 
many people, it is not widely studied, and hence is an important area of study for the 
identification of new treatments. 
B. Structure of Hemoglobin 
The majority of sickle cell disease cases are caused by a single point mutation in the p­
globin subunit of hemoglobin, resulting in a structure that can polymerize under deoxygenated 
conditions and form fibers. The general structure of normal hemoglobin, the oxygen-carrying 
protein, is a tetramer that is composed of two pairs of subunits that can carry up to four 
molecules of oxygen. The subunits can be formed from seven different polypeptide chains (a, p, 
Ar, Gr'�' s, and s), each of which arises in some form of hemoglobin during different points in 
development.4 Adult hemoglobin (Hb A) is comprised of a and p subunits, with an overall 
structure of a2P2. Another common type of hemoglobin, fetal hemoglobin (Hb F), is present 
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primarily in fetuses and has the structure atY2. Fetal hemoglobin has a stronger affinity for 
oxygen than adult hemoglobin so it can capture oxygen molecules from the maternal 
hemoglobin. 
Two pairs of two subunits come together to make the overall tetramer, forming the 
structure seen in Figure 1.1 .  Each subunit contains a heme group, 
whose structure is shown in Figure 1.2. It has a ferrous atom in 
the center that coordinates with five ligands when not bound to 
oxygen, or six ligands when bound to oxygen. Four of the 
coordinate covalent bonds of the ferrous atom are to the pyrrole 
nitrogen atoms of the porphyrin, which lies in a plane. The fifth 
bond is to the imidazole of a histidine in one of the a helixes, His 
F8, which is perpendicular to the plane of the porphyrin ring. 
This residue is known as the proximal histidine. If oxygen is 
bound to heme, it occupies the sixth coordination site and also 
coordinates with the distal histidine (His E7). These interactions 
are shown in Figure 1.3. The coordination of heme to the various 
ligands is important for the cooperative binding of oxygen to 
hemoglobin. 
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Figure 1.1 A ribbon diagram 
structure of adult hemoglobin 
bound to four oxygen molecules 
with the heme groups indicated. 
The two a subunits are colored 
blue and green and the two p 
subunits are colored red and 
purple.5 
OH 
Figure 1.2 The structure of the 
heme group. 
(; hE'lix ---
H hE'lix 
Figure 1.3. A cartoon of the heme molecule coordinating with His F8 and His E7 through 
oxygen, with the oxygen molecule shown in red.6 
C. The Binding of Hemoglobin to Oxygen 
Hemoglobin exhibits positive cooperative binding to oxygen, which means that the 
binding of each oxygen molecule to one subunit makes it easier for the next oxygen molecule to 
bind to another subunit, and the dissociation of each oxygen molecule makes it easier for the 
next oxygen molecule to dissociate. Myoglobin, which essentially can be viewed as one subunit 
of hemoglobin, requires a 8 1  fold change of concentration of oxygen to increase the percentage 
associated with oxygen from 1 0% to 90%; however, hemoglobin only needs a 4.8 fold change to 
attain this percentage change.5 This cooperativity is due to the effect of the geometry of the heme 
group on the conformation of the protein. When heme is not bound to oxygen, it is slightly bent, 
with the ferrous atom out of the plane of the rings. However, when it binds to oxygen, the heme 
adopts a flat conformation with the ferrous atom in the plane. This is relatively difficult due to 
the large size of the Fe2+ atom and can only happen when the free energy of the bond formation 
3 
overcomes the ring strain of the flat heme conformation.5 This change causes the His F8 residue 
to be pulled towards the porphyrin ring, which moves the F helix and causes subsequent 
destabilization of the interaction of the subunit with the adjacent subunit. This results in a 
conformational change of the nearby subunit that allows it to bind to oxygen easier. The 
oxygenated conformation of hemoglobin is referred to as the "R" or "relaxed" state, while the 
deoxygenated conformation is the "T" or "tense" state.5 
Many factors can influence the equilibrium between the T and R states of hemoglobin. 
For example, hemoglobin releases protons when shifting from the T state to the R state, so a 
decrease in pH causes a shift in the equilibrium back to the T state. This ability to respond to pH 
allows hemoglobin to adequately deliver oxygen in oxygen-deprived muscles, as the pH changes 
due to biological cues such the dissociation of carbonic acid or the formation of lactic acid. 
Another factor that affects the conformations of hemoglobin is the molecule 2,3-
bisphosphoglycerate (BPG), which stabilizes the T state of hemoglobin and is used by the body 
to regulate oxygenation levels. 
D. Structure of Sickle Cell Hemoglobin and Its Polymers 
Sickle cell hemoglobin (Hb S) results from a point mutation in the gene coding for the p 
subunit that allows the protein to polymerize in the deoxygenated state. The gene for the p 
subunit in humans is on chromosome 1 1 , and a change from an adenine base to a thymine base 
creates a codon that codes for valine (V) (GTG) instead of glutamate ( E) (GAG).? This mutation 
takes place at the sixth position of the p chain, and therefore is known as an E6V mutation. This 
mutation replaces a negatively charged residue with a nonpolar residue that can interact with 
residues of another hemoglobin protein when hemoglobin is deoxygenated, resulting in 
polymerization. The crystal structure of polymerized deoxygenated hemoglobin reveals that the 
4 
valine interacts with a hydrophobic pocket containing alanine, phenylalanine, and leucine 
between the E and F helices of another hemoglobin.8 This lateral contact produces a double 
strand of hemoglobin tetramers, as shown in Figure 104. This polymer, which is also stabilized 
through axial contacts between two adjacent proteins in one strand, is 2 1 0  A thick and has a 
slight helical twist. The end result of this polymerization is a polymer with fourteen filament 
strands that has decreased solubility in aqueous environments. 
Figure 1.4 The structure of polymers of deoxygenated sickle cell hemoglobin. On the diagram on 
the left, the heme groups are shown in red and the valine mutations involved in the lateral 
contacts connecting the two strands are shown in blue, and the rest of the protein is shown as a 
transparent molecular surface. On the diagram on the right, the same coloring system is used, and 
the backbone of the protein is shown in white.9 
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The lateral contacts holding the two strands together are not just held together through 
hydrophobic interactions, but are also stabilized by hydrophilic interactions with nearby residues. 
These other interactions are also important for the polymerization of Hb S and subsequent 
consequences of sickle cell disease. 
E. Phenotypes a/Sickle Cell Disease 
The polymerization of hemoglobin has a 
variety of effects in the body. As the hemoglobin in 
the red blood cells polymerizes, the erythrocyte 
deforms into the characteristic sickle shape that is 
associated with the disease. Figure 1.5 shows a 
comparison of sickled red blood and normal red 
blood cells. This causes a number of complications. 
One of the main problems that can arise is that the 
abnormal shape and increased expression of surface 
Figure 1.5. Sickled red blood cells 
formed by the polymerization of 
deoxygenated sickle cell hemoglobin 
compared to normal red blood cells as 
seen in a peripheral blood smear. The 
sickled cells are indicated by the arrows. 1 
adhesion proteins on the red blood cells can block small blood vessels and cause vaso-occlusion, 
as shown in Figure 1 .6.  This results in tissue ischemia, which causes pain and organ damage.3 
The pain is a major hindrance to the nonnal life of patients, and the organ damage can build up 
to severe levels. Another issue with hemoglobin polymerization is that it can cause hemolysis, or 
the rupture of red blood cells, because of the deformation of the cells when polymerization 
occurs. The normal life of a red blood cell is about 1 00 to 120 days, while sickle red blood cells 
live for only a little more than a week.3 Hemolysis causes anemia, pulmonary hypertension, and 
jaundice. Another common issue in sickle cell patients that usually arises in childhood is splenic 
sequestration. The spleen has narrow blood vessels and is overworked due to the large volume of 
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damaged red blood cells, so it frequently undergoes infarction and is nonfunctional in sickle cell 
patients.3 This leads to patients that are more susceptible to infection. Another problem in sickle 
cell disease patients is acute chest syndrome, which arises from a variety of complex issues such 
as infections, pulmonary emboli, and pulmonary infarctions and is a major cause of mortality. 
Additionally, many other patients die from compound organ damage caused by many vaso-
occlusion events. Due to these symptoms, sickle cell disease is the cause of many hospital visits, 
morbidity, and mortality of the world population. 
A!S Cap,lane. 
W/ 
B 
Po$lcaplflaty 
Venules 
Dense cell 
ttapplng and 
retrograde 
blockage 
Figure 1.6 The process of vaso-occlusion. The red blood cells adhere to the wall of the blood 
vessel and build up until the flow of blood through the vessel is stopped, causing pain and organ 
damage. 10 
F. Current Therapeutics/or the Treatment a/Sickle Cell Disease 
One of the few predictors of how severe the sickle cell disease will present itself is the 
amount of fetal hemoglobin in the blood. The greater the amount of Hb F, the better the outcome 
for the patient. Fetal hemoglobin production usually drops nine to eighteen months after birth, 
and stabilizes after three to four years. However, a small amount of Hb F still remains in the 
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blood, around 0.5-2% of total hemoglobin in regular adults and 3-20% in sickle cell disease 
patients.9 Because the structure ofHb F is atY2, it is not affected by the sickle cell mutation in the 
p subunit. Higher concentrations ofHb F work to decrease the concentration ofHb S and results 
in less polymerization and therefore fewer complications of the disease. The only current FDA­
approved treatment for sickle cell disease is hydroxyurea, which raises the levels ofHb F in the 
blood. Hydroxyurea is usually used as an anti-cancer agent, and is a ribonucleotide reductase 
inhibitor. Through its cytotoxic activity, it can produce stress on the production of red blood 
cells, which triggers the body to increase the expression of fetal hemoglobin over adult 
hemoglobin.] 1 Unfortunately, the response to the treatment greatly varies between patients, and it 
frequently has undesirable side effects, making it unusable in some patients. The only other 
treatments available for SeD patients are those that manage the symptoms, such as pain 
relievers, hydrating agents, and organ transplantation to replace damaged organs. It can be cured 
with a bone marrow transplant, but this is a risky and expensive procedure, and it is difficult to 
find suitable donors that do not produce an immunogenic response. 
There are a variety of treatments that are currently being investigated as better 
alternatives to hydroxyurea for sickle cell disease. One area of research is finding molecules that 
can prevent polymerization. For example, there is a class of compounds that form Schiff-base 
adducts with Hb S and increase its affinity for oxygen, decreasing the levels of hemoglobin in 
the T state and reducing the amount of polymerization. 12 Another area of research is focused on 
decreasing the adhesion of the red blood cells to the endothelium of the blood vessels, which 
would reduce the occurrence of vaso-occlusion events.13 A third area is working to restore nitric 
oxide bioavailibility. Nitric oxide, or NO, is a vasodilator that is made bioavailable by binding to 
hemoglobin.5 This function is disrupted in polymerized hemoglobin and free heme scavenges 
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NO; therefore, there is less NO available to the blood vessels. This causes the vessels to be more 
constricted than usual and results in an aggravation of vaso-occlusion.2 There is also quite a bit 
of work being done on gene therapy. For example, Purumbet et al. were able to insert a lentiviral 
vector with gamma globin exons and beta globin regulatory units and increase the concentration 
of fetal hemoglobin in a murine model to a level where the amount of polymerization decreased 
significantly.14 However, gene therapy comes with a variety of problems, including gene 
delivery and immune responses to the gene. Therefore, an effective treatment for sickle cell 
disease is still needed. 
G. Our Approach 
Our group is attempting to find a ligand that will bind to sickle cell hemoglobin and 
inhibit polymerization or increase the delay time before polymerization. We utilize screening 
techniques such as phage display or one-bead-one-compound library screens to identify novel 
tightly binding ligands, then test these high affmity ligands to determine whether they can affect 
the polymerization of hemoglobin. 
Ligands that have an effect on polymerization could operate through two distinct 
mechanisms. One way is through interaction with the residues in either the hydrophobic pocket 
or the mutated valine and directly blocking polymerization. Akbar et al. developed a 15 amino 
acid peptide that mimicked the hydrophobic pocket in the EF helix acceptor region and inhibited 
polymerization in vitro by interacting with the valine mutation,9 showing the feasibility of this 
approach. Another approach is through interaction with hemoglobin molecule in a way that 
stabilizes the R state and results in decreased deoxygenated hemoglobin. An example of this 
method is 5-hydroxymethyl-2-furfural, a Schiff base that works as mentioned above and was 
shown to inhibit sickling of SS cells at low drug concentrations.12 These different mechanisms 
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are shown in Figure 1 .7. To fmd ligands that can work through either of these two mechanisms, 
the general approach of our group is to identify novel peptidic ligands for hemoglobin, 
synthesize them using solid phase peptide synthesis techniques, and test them against 
hemoglobin to determine whether an effect on polymer formation is found . 
.. 
(f r 1 � r 1 
Figure 1.7 The possible mechanisms of inhibiting the polymerization of sickle cell hemoglobin. 
In the first mechanism, a ligand binds somewhere on the hemoglobin molecule and stabilizes the 
T state. In the second mechanism, a ligand binds to the hydrophobic pocket and prevents it from 
interacting with the mutated valine. In the third mechanism, a ligand binds to the mutated valine 
and prevents it from interacting with the hydrophobic binding pocket. 
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Chapter II: Phage Display 
A. Phage Display Overview 
Previously in our group, a phage display selection was used to identify novel high affinity 
peptides for deoxygenated hemoglobin. Phage display is a combinatorial technique that allows 
for rapid screening of a diverse library of biological compounds such as peptides. A population 
of phage expressing peptides on their surfaces are used to screen a library against target 
molecules and select for the most tightly binding ligands. This technique was first introduced by 
G.P. Smith in 1985, and has since then become a powerful tool for elucidating the structures of 
tightly binding ligands with a wide array of applications. 
The phages used in displays are filamentous bacteriophages that are engineered to 
express a library of peptides on their surfaces. These rod-shaped phage are usually from the 
Inoviridae family and the genus Inovirus and include members such as M13 ,  fl and fd. 1 6 M13  is 
the most commonly used phage. These phage infect Gram negative bacteria that contain F­
plasmids. The M13  phage has a circular genome comprised of ss-DNA (single-stranded DNA) 
made up of 6000 to 8000 bases that code for eleven proteins, including coat proteins, DNA 
replication proteins, and assembly proteins. 1 7  These phage are used because they can tolerate the 
insertion of foreign DNA and are able to express the resulting fusion protein without disrupting 
the normal function of the phage. They are also stable under a variety of harsh conditions such as 
extreme temperatures and different pH ranges. Finally, they are non-lytic and do not cause 
bacteria to burst, so they can accumulate to a high concentration within the bacterial cells. These 
phage are genetically modified to express a library of compounds, such as peptides or proteins, 
as a fusion protein with one of their coat proteins. 
1 1  
The M13  phage have five different coat proteins named pIlI, p VI, P VII, P VIII, and pIX.1 6 
These proteins have all been made to express peptide libraries on their N-terrnini or C-terrnini. 
The most commonly used coat proteins for phage display are pIlI, the minor coat protein, and 
p VIII, the major coat protein, because they are the most accessible proteins for screening. p VIII 
is present in high quantities on the outside of the phage, with about 2700 copies tightly packed 
expressed on the surface of the phage. These proteins can only handle peptide fusions of about 
ten residues or less onto their N-terrnini, as longer peptides interfere with the assembly process 
of the phage. In p VIII phage displays, the affinity of the ligands obtained is usually decreased 
because so many copies of p VIII are displayed in a small space on the phage. Therefore, 
sometimes phagemids, which are plasmids that result in the expression of a mixture of wild type 
and fusion proteins, are used to reduce the number of recombinant p VID, 18 but these require the 
use of helper phage to ensure proper working of the screen. The more commonly used capsid 
protein is pIlI. This protein is usually involved in interacting with the F-pilus of the bacterial 
cells and modulating infection.19  It can tolerate larger insertions and can handle fusion proteins 
with peptides of up to 50 residues inserted before its normal function is disrupted. It has a 
different expression pattern than p VIII and is instead present in three to five copies on the cap of 
one phage. The locations and expression patterns of these two coat proteins are shown in Figure 
11. 1 .  Because pIlI has reduced valency compared to p VIII, using it for phage display usually 
results in higher affinity ligands with � values around 1 - 1 0  JlM, compared to p VIII � values of 
around 10-100 JlM.1 6 In our phage display, we utilized M13 phage with the M13KE cloning 
vector, which results in the expression of peptides on the pIlI proteins of the phage. 
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Single-stranded DNA 
"'-Gene VIII peptide 
Figure n.l An illustration of the location of p VIII and pIlI coat proteins. As can be seen in this 
cartoon, p VIII is expressed at high levels all over the phage, and pilI is expressed in low levels at 
one end of the phage.20 
B. Phage Display Libraries 
The libraries expressed on the surface of the phage can consist of various types of 
compounds. The most common are peptide libraries. The combinatorial library is made through 
recombinant techniques to produce random oligonucleotides which are then introduced into the 
phage genome and result in the random expression of amino acids.16 All of the twenty natural 
amino acids can be used which produces 20n possible peptide sequences, where n is the number 
of residues in the peptide chain. Practically, due to stop codons and degeneracies in the genetic 
code, only about 109 peptides of any length can be displayed in a phage library. A common way 
to produce the random oligonucleotides is through an (NNK) codon degeneracy, where N is a 
mixture of equal amounts of the four DNA nucleotides and K is an equal mixture of guanine and 
thymine.16 This reduces the number of stop codons that arise randomly. There are also a few 
selective pressures that result in biases in the displayed peptide library. For example, arginine 
and cysteine residues can interfere with the secretion of pIlI, so they can be selected against.19 In 
spite of these biases, which can be avoided through extra steps if desired, a massive number of 
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peptides can be displayed and screened. The large number of peptides produced that can be 
screened rapidly makes this technique very powerful and ensures the selection of very tightly 
binding ligands. Using this method, peptides can be found that can be as specific and tightly 
binding as antibodies. Since peptides are much easier and cheaper to produce than antibodies, 
this is an exciting avenue for searching for novel drugs and pharmaceutical targets.zo 
After the phage are engineered to express this wide diversity of compounds, they are 
screened against targets to find the highest affinity ligand. The most common method for in vitro 
phage display screening is biopanning. In the panning method, the target is first immobilized to a 
plate or well. Then, the phage are added and allowed to bind. The unbound phage are removed 
through a series of washing steps, each with increasing stringency to ensure that the phage that 
remain bound are only the high affinity phage.17 After the washing, the phage is eluted with 
either the ligand of the enzyme, by a pH change, by using a denaturant, or some other condition 
that will disrupt the interaction between the phage and the enzyme. Because filamentous phage 
are very stable, they can undergo this step without being damaged. Finally, the eluted phage is 
cultured with bacteria to amplify it, and the screening process is repeated one to three times to 
ensure that only the highest affinity phage are selected. Finally, the DNA sequences of the top 
hits are obtained and the peptide sequence can be determined. The overview of this process can 
be seen in the diagram in Figure 11.2. 
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phage,each 
displaying a 
different pep­
tide sequence, 
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a plate coated 
with the target. 
Unbound 
phage are 
washed away . 
Specifically-bound 
phage are eluted 
with an excess of 
a known ligand for 
the target, or by 
lowering pH. 
After 3 rounds, 
individual clones 
are isolated and 
sequenced. 
Figure 11.2 The overview of the phage display cycle. The phage library is allowed to bind to the 
target in step one. In step two, the phage with lesser affInity are washed away. In step three, the 
tighter binding phages are eluted and amplified. In step four, the cycle is repeated two more 
times with the amplified phage. After the third cycle, the phage DNA is isolated and 
sequenced. 19 
Phage display selection experiments can be carried out with a variety of biological 
compounds. While peptides are the most common, proteins and antibodies can also be expressed 
in a combinatorial fashion. Unnatural amino acids, such as D-amino acids, and cyclic peptides 
can also be expressed in a phage display. Phage display can be done in vivo to find ligands that 
can target a specific organ or tissue of the body. During an in vivo phage display, the phage is 
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delivered into a live animal, the animal is sacrificed, and the target organ or tissue is lysed and 
the phage present identified.21 Finally, organisms besides phage can also be used to screen 
diverse libraries. Two common examples are bacteria and yeast, both of which can be engineered 
to express peptides or proteins fused with their cell surface proteins.22 However, these organisms 
are more complex than phage and the other proteins on their surface are more likely to have 
undesirable interactions with the expressed fusion proteins. 
Phage display selection experiments have many advantages over other screening 
processes. One advantage is the wide diversity of compounds that are expressed. As mentioned, 
there are usually about 109 possible peptides displayed; in comparison, chemical libraries that are 
used in high-throughput screens consist of around tens of thousands of compounds.23 Another 
advantage is that this large library can be very rapidly screened, as the phage are small and easily 
amplified, which allows for the quick determination of high affinity ligands. A third advantage is 
that the genotype and the phenotype of the phage are linked, since the peptide is displayed on the 
surface of the phage with the DNA containing the sequence inside of the phage. This makes it 
applicable for versatile functions while still allowing the easy identification of peptide 
sequences. Because of these advantages, phage display has been used in a wide variety of 
applications with great success. 
B. Experimental 
Previously in our group, a phage display was performed against deoxygenated sickle cell 
hemoglobin to identify novel high-affmity ligands of the protein. All of the screens were done in 
an anaerobic chamber. First, a solution of 2 mg/mL of Hb S and 5 mg/mL of sodium dithionite in 
PBS was shaken with a plate for three hours to coat the plate with deoxygenated Hb S protein. 
The supernatant was removed and analyzed by ultraviolent visible spectroscopy to ensure that 
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the hemoglobin was deoxygenated. The spectrum showed a single peak at 554 nm, which is 
indicative that the hemoglobin was in its deoxygenated state. Then, a buffer comprising of 0. 1 M 
NaHC03 and 5% evaporated milk (blocking buffer) was added to plate and incubated with the 
Hb S for an hour. The supernatant was removed and the plate was firmly slapped on a paper 
towel to remove residual solution. The plate was rapidly washed six times with 0.1 % TBST and 
was firmly slapped between each washing. A solution of 1 .0 mL of 0. 1 % TBST and 2 x lOll of 
M13 phage was added to the plate and incubated for one hour. The non-binding phage were 
discarded by removing the supernatant and washing ten times with 0. 1 % TBST as described 
above. The bound phage was eluted by shaking 1 mL of a 0.2 M glycine-HCI with a pH of2.5 on 
the plate for ten minutes. After elution, the solution was neutralized with 150 11M of 1 M Tris­
HCI. 
The eluted phage was titered to determine the concentration of phage eluted. To titer, 
serial dilutions of the phage were prepared and added to a culture of ER2738 (an E. coli strain). 
These were cultured on plates with antibiotics and X-gal. This allowed plaques to be counted and 
the number of phage in the sample determined. 
The eluted phage were amplified by incubating them in a culture of mid-log ER2738 for 
4.5 hours at 3TC. Using centrifugation and PEG/NaCI precipitation, the phage was isolated from 
the bacterial cells and titered. The amplified phage was used for a second round of panning, 
using 0.5% TBST in the wash steps but keeping the other steps constant. The eluted phage was 
titered, amplified, then titered again. Finally, a third round of panning with the phage was done. 
This phage was titered. Bacteria from the plaques from the titer were cultured at 3TC for 5 hours 
and the phage was obtained through centrifugation and PEG/NaCl precipitation. The phage DNA 
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was isolated through centrifugation and sent for sequencing. The following peptide sequences 
were obtained: 
ZSF32 Q-T-H-N-T-E-V 
ZSF33 S-L-S-D-W-P-Q 
ZSF34 F-T-P-S-S-D-V 
ZSF35 T-W-F-R-M-L-S 
ZSF36 H-L-S-L-T-H-H 
ZSF37 H-H-Q-F-S-F-N 
ZSF38 G-S-G-N-L-K-T 
ZSF39 E-P-W-N-P-I-P 
No consensus sequence is seen in these peptides. However, this is not surprising, as the 
ligands were being screened for general binding affinity for Hb S and not for one particular site 
of Hb S. These molecules were then synthesized and tested for any effect on polymerization. 
One molecule, ZSF39, showed to have an inhibitory effect on polymerization. 
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Chapter III: Peptide Combinatorial Library Synthesis 
A. Overview of Pep tides as Therapeutics 
Peptides are defined as short chains of less than 50 amino acids. Naturally occurring 
peptides have a diverse range of applications in the body, including roles as signaling and 
regulatory molecules, neurotransmitters, and antibiotics.24 They have also been used as 
therapeutic agents and have great potential in the upcoming pharmaceutical market. Currently, 
there are over 60 FDA approved peptide drugs and over 125 peptides in clinical and preclinical 
trials.25 The market for peptide drugs has increased over the last decade and is expected to 
continue expanding in the next few years, growing from a market of $14. 1 billion in 20 1 1  to a 
predicted $17 billion in 20 1 8.26 This growth in the market is due to peptide therapeutics 
occupying the niche between small molecule drugs and large protein and antibody 
pharmaceuticals. As the drug market evolves, an increase in the number of peptide drugs is 
expected. 
Peptides as drugs have a number of advantages. Compared to antibodies and proteins, 
they trigger less of an immune response and have better efficacy because they penetrate farther 
in tissues due to their smaller size.27 They also are cheaper to make. Compared to small organic 
molecules, peptides can have better specificity and are less toxic because the products of their 
catabolism are amino acids, which are not harmful to the body. Recent updates in technology for 
peptide screening and synthesis as well as an increased push for safety in pharmaceuticals have 
attracted more attention for use of peptides as drugs. 
Peptides do have limitations as pharmaceuticals. They have low bioavailability because 
they are easily metabolized before they can reach their target. One main issue is that they are 
subject to proteases and cannot be taken orally or they will be easily degraded in the 
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gastrointestinal tract. They also have difficulty crossing the GI epithelial cells. Consequently, 
most of the peptide-based drugs on the market must be delivered intravenously?6 This is not 
ideal from a patient perspective and can make regular administration difficult. Another issue is 
that peptides have a short half-life in the body, and are cleared from the plasma rapidly through 
hepatic and renal elimination. They also have a hard time crossing cellular membranes because 
of their relative hydrophilicity. 
Strategies have been developed to overcome these limitations of peptide pharmaceutical 
agents. One way is to use unnatural amino acids or other modifications to the basic structure of 
the peptide to create a molecule with similar properties that will not be targeted by proteases. For 
example, the drug desmopressin, an analogue of the nine-amino acid long hormone vasopressin, 
Was created by replacing the L-arginine at the eighth position with a D-arginine. This allows 
desmopressin to be taken orally because it is more resistant to protease activity and can cross the 
epithelial cells of the gastrointestinal tract more easily, while vasopressin has very low 
bioavailability when taken orally?8 Another strategy is to co-administer the peptide with a 
protease inhibitor to protect the peptides.29 A defense against plasma clearance is to attach 
groups to the peptide that target serum albumin, a major blood protein, which will then carry the 
compound through the blood. A second strategy against elimination is to conjugate the peptide 
with polyethylene glycol in a process known as PEGylation and increase the size of the overall 
compound so it is not renally excreted. PEGylation also draws in a larger solvation shell around 
the peptide which can protect it against proteases and make it less immunogenic?4 The peptides 
can also be delivered in a packaging technique, such as liposomes or nanoparticules, that 
encapsulate the peptide and help shield it against potential degradation?8 Utilizing these 
techniques can greatly increase the potential of peptides as therapeutic agents. 
20 
B. The Structure of Peptides 
Peptides are comprised of amino acid building blocks. The general structure of an amino 
acid is shown in Figure IlLI. An amino acid consists of a compound containing an amine group, 
a carboxylic acid functional group, and a side chain, all attached to a central or a-carbon. 
Generally, amino acids exist as zwitterions in solution, as the amine functional groups are 
usually protonated and the carboxylic acid functional groups are usually deprotonated. The 
specific properties of the amino acid are determined by the side chain, also known as the R 
group. These side chains range from nonpolar functional groups to polar groups or acidic and 
basic groups and are unique to each amino acid. There are twenty standard amino acids that 
make up the majority of the residues found in the body, which are shown in Figure IIl.2. Almost 
all of the standard amino acids are chiral and are found in nature almost exclusively as the L 
enantiomer. The amino acids glycine and proline are exceptions to the typical amino acid 
structure. Because glycine'S side chain is a hydrogen atom, it is achiral and has a more flexible 
structure than most amino acids. The structure of proline is also unusual because its side chain is 
a ring, making it a secondary amine.30 
H
, � P 
N-C-C 
/ I \ 
H H O-H 
Figure ID.I The structure of a general amino acid. Usually, the carboxylic acid moiety is 
deprotonated and the amine group is protonated, and the structure exists as a zwitterion. The "R" 
is the side chain, which varies between each amino acid. 
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Figure llI.2 The structures of the twenty natural amino acids. Depending on their side chains, 
they have different properties that give them different functions in the body.24 
C. The Synthesis of Peptides 
The coupling of amino acids results in the formation of peptides. This is done by a 
condensation reaction between the carboxylic acid group of one amino acid and the amine of 
another amino acid, forming water and a peptide bond connecting the two residues, as displayed 
in Figure Ill.2. This can be repeated to form a polypeptide chain. In nature, this process is known 
as translation and is carried out in the ribosome. Translation is used to create longer peptide 
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chains that eventually adopt tertiary structures and become proteins. Peptides can also be 
synthesized via solution phase synthesis or solid phase synthesis. 
H�ly�ylOH 
o 
o R2 
Figure 111.3. The condensation reaction between two amino acids that results in the formation of 
a dipeptide. 
In solution phase synthesis, all of the reactants are dissolved in a solvent and reacted 
leading to product. A major drawback of this technique is that the peptide intermediates need to 
be purified through conventional methods after each step. This can lead to a very time 
consuming synthesis if longer chains are desired. A heterogeneous phase synthesis of pep tides 
linked to a solid support known as solid phase peptide synthesis (SPPS) is usually utilized 
because of its ease and utility?4 In SPPS, the peptide is connected to a solid resin bead via a 
linker compound and the reagents for synthesis are dissolved in a solvent. The reactions all occur 
in one reaction vessel fitted with a filter that allows for easy removal of liquids. Because of this 
facile removal of the excess reagents and impurities through filtration coupled with washing 
steps, SPPS has extremely simplified purification steps compared to solution phase synthesis. 
Another advantage of SPPS is that a large excess of reagents can be used, usually between 2-4 
equivalents, so the reactions are driven almost all the way to completion. The final yield of the 
peptide is effectively quantitative, usually above 99.5%.30 SPPS is also useful because unnatural 
amino acids or other modifications can be easily introduced, and it can be scaled up to produce 
short peptides in high numbers.27 Because of these advantages, most peptide chemists use SPPS 
to synthesize their compounds. 
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In SPPS, the growing peptide chain begins with a solid resin with linker molecules. The 
resin, which is comprised of many beads, is generally made of polystyrene crosslinked with 
divinylbenzene. The resin utilized in this project was TentaGel resin, which is comprised of 
polyethylene (PEG)-functionalized polystyrene24 and has a diameter of about 100 IlM per bead. 
The resin used must meet certain criteria to ensure successful peptide synthesis. It must be 
physically stable and not be damaged during the filtering process. It must also be chemically 
inert and not participate in the reactions during the peptide synthesis. It must be able to swell in 
solvent so all of the reactive sites on the bead are accessible.3 1  The beads each have about 1013 
reactive sites and can swell to about six times their dried volume to reveal all of the sites. These 
reactive sites have linkers attached that will react with the first amino acid of the peptide chain 
and ensure that proper spacing of the growing peptide chains is maintained in order to prevent 
aggregation. 
After the C-terminus of the first residue is attached to the linker, a series of repeating 
steps is used to sequentially add amino acids onto the growing peptide chain until the desired 
molecule is obtained. Unlike peptide synthesis in the body, peptides are synthesized from the C­
terminus to the N-terminus in SPPS. First, the carboxylic acid functional group of the amino acid 
that is being added must be activated, which is often achieved using HBTU. HBTU, the structure 
of which is shown in Figure III.4, is an uronium reagent that reacts with the carboxylic acid and 
produces a reactive ester species which the N-terminus of the existing peptide chain can attack.30 
HOBt, or I -hydroxybenzotriazole, is also used in amino acid coupling as a racemization 
suppressant. It is a trapping agent that ensures that the reaction does not result in racemization. 
Its structure is seen in Figure III .S .  These two reagents are added with the incoming amino acid 
in a basic environment to facilitate the coupling of the amino acid onto the existing peptide 
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chain. The reaction of the HOBt and HBTU with the amino acid that is being added to the chain 
is depicted in Figure III.6. 
Figure 111.4 The structure of 
HBTU, the coupling reagent used 
to active the carboxylic acid of 
the incoming amino acid. 
(Y. � ·· �. 'N 
�N' 
\ 
OH 
Figure 111.5 The structure of 
HOBt, the trapping agent used to 
prevent racemization of the 
growing peptide chain. 
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Figure 111.6 The mechanism of amino acid coupling using HOBt and HBTU in a basic 
environment. In the first step, the amino acid to be added attacks the HBTU, forming an 
activated ester. Next, HOBt attacks the amino acid, forming another activated ester that cannot 
be racemized. Finally, the amine of the peptide chain attacks the incoming amino acid, forming 
the peptide bond and completing the coupling. 
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The amino ends of the incoming amino acids, known as the � amino groups, are 
protected to ensure that only one residue is added to each chain and that there are no undesired 
side reactions. Fmoc (9- fluorenylmethoxycarbonyl) groups are commonly used to protect these 
ends. The Fmoc protecting groups are base labile and are removed after every amino acid 
addition. The removal of an Fmoc group by morpho line, a weak base, is depicted in Figure III. 7. 
Reactive side chains of amino acids also need to be protected to ensure they do not participate in 
side reactions; however, these protecting groups must be orthogonal to the Fmoc groups because 
they are not removed until all of the amino acids have been added, and therefore are usually acid 
labile and removed using trifluoroacetic acid (TF A).24 The structure of the common side chain 
protecting groups can be seen in Figure III.8 . 
o=c=o + NH2 
I R 
Figure III.7 The structure of a peptide chain on a resin with an Fmoc protected � amino group, 
and the removal of the Fmoc compound by morpho line. 
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Figure UI.8 Typical amino acid side chain protecting groups for Fmoclt-Bu coupling. "Trt" 
stands for trityl and "Pbf' stands for pentamethyl-2,3-dihydrobenzofuran-5-sulfonyl. These are 
used to ensure that reactive side chains do not undergo undesirable reactions and are removed by 
TFA at the end of the synthesis.24 
After the first amino acid is added to the resin, a cycle of deprotection of the Fmoc group 
and coupling of the next amino acid is repeated until the desired sequence is reached. A 
depiction of this cycle can be seen in Figure III.9. The process can be tracked using a ninhydrin 
test, or a Kaiser test, to monitor whether primary or secondary amines are present in order to 
determine whether reactions have gone to completion. This simple two-step method makes 
peptide synthesis facile and allows for modifications such as the addition of an unnatural amino 
acid. It also can be automated easily, so many automated peptide synthesizers have now been 
made and fine tuned to synthesize many different types ofpeptides.32 Using this method, peptide 
chains with a maximum of about 50 residues can be synthesized easily and in high yield. After 
the peptide chain is synthesized, it is cleaved from the resin using TF A, which also cleaves the 
side chain protecting groups. After cleaving, the peptide can be purified through standard 
analytical methods such as chromatography and identified using mass spectrometry. 
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Figure 111.9 A depiction of the cycle of SPPS. After the first amino acid is initially bound to the 
resin, it is washed and deprotected by a weak base. It is washed again and another amino acid is 
coupled using coupling reagents. This two step cycle can be repeated until the desired peptide is 
synthesized. It is then cleaved from the resin. In this figure, "P" represents Fmoc protecting 
groups. 
D. Combinatorial Peptide Libraries 
Another advantage of SPPS is that it can easily be adapted to combinatorial chemistry 
and used to make an incredibly diverse library. These libraries can be used in screens to identify 
lead compounds with a desired effect from a huge number of possibilities. Combinatorial 
chemistry has a few advantages over traditional chemical libraries screening. It can be used to 
generate huge libraries quickly, instead of synthesizing each compound individually. Also, 
because a larger number of compounds are being screened, it is more likely that a substantial hit 
will be identified.3 1  
To synthesize a combinatorial library a one-bead one-compound technique is  used. In this 
method, which is also known as a split-and-mix synthesis, the positions of the amino acids are 
randomized. To do this, beads are split into equal groups and each individual group of split beads 
receives a different amino acid. Then the groups are all re-pooled and thoroughly mixed. The 
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splitting process is then repeated so each group has an equal amount of beads from the previous 
groups, and another randomized amino acid is added. This method is repeated until the chain of 
the desired length is synthesized. This method ensures that every possible peptide is made, and it 
should give an equal amount of each compound.32 For a peptide library, the number of 
compounds generated is equal to An, where A is the number of amino acids used in synthesis 
(usually 20) and n is the number of amino acids in the final sequences. This library synthesis is 
known as one-bead one-compound because each bead only contains peptides at its reactive sites 
with a single sequence. This allows for screening based on bead and easy determination of the 
sequence of the peptides on that bead. 
,· Il .. JiOB.t, H131V, TEA 
' R, • - HOBl, HBTLi, TEA 
" R , .. 1009:, HB'1U, TEA 
+ R. .. - l lO!ll, EllTli, TE..'" 
Figure m.l0. An outline ofthe synthesis of a combinatorial library. First, the resin beads are 
split into equal fractions and a different amino acid is added to each fraction. The beads are 
pooled again, mixed equally, then split into fractions again. Each fraction contains an equal 
number of beads from each fraction in the previous step. Another randomized amino acid is 
added to each fraction. This process can be repeated until the chain of desired length of 
randomized positions is synthesized. 
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The sequences of unknown peptides can be identified through processes such as Edman 
degradation. In Edman degradation, the amino acid at the N-terminus of the peptide is reacted 
with phenylisothiocyanate and cleaved from the chain. The resulting compound produced can 
then be identified via HPLC or some other analytical method. This cycle is repeated sequentially 
until the entire peptide has been sequenced. The reaction and removal of the N-terminus in 
Edman degradation can be seen in Figure III. I I . 
o (phenyt�anate) 
N=C:S 
+ 
Edman Cycle 
HPLC separation 
Figure 
ill. 1 1  A 
general 
overview of Edman degradation. The N-terminus of the peptide to be identified is reacted with 
phenylisothiocyanate and forms a PTH-amino acid compound that can be identified by a 
characteristic HPLC peak. This cycle can be repeated until all of the amino acids comprising the 
peptide have been identified.33 
E. Goal of the Combinatorial Proline-Rich Peptide Library 
Combinatorial peptide chemistry was utilized in this project to generate a peptide library 
based on the results from the phage display. The inhibition of polymerization by ZSF39 is 
intriguing, as ZSF39 contains three prolines, the amino acid with a ring structure as a side chain. 
Proline is unique because its constrained conformation produces a kink in the backbone of the 
30 
peptide. Three prolines in a seven-mer peptide suggests that the proline have a significant effect 
on the properties and structure Qf the peptide. Therefore, we wanted to further investigate how 
the structure of this peptide affects polymerization and if the non-proline positions of ZSF39 
could be optimized to produce a stronger effect on polymerization. To do this, a combinatorial 
library was synthesized in which the three proline positions were kept constant and the other 
positions of the peptide were randomized. The final compounds had the sequence seen in Figure 
III. 1 0. 
Figure 111.10 The sequence of the peptides synthesized in the combinatorial library, 
where "X" is a randomized amino acid. 
F. Experimental 
The solid support used for the synthesis was 200 mg (0.05 1 8  meq) of TentaGel R-NH2 
resin, a non-cleavable resin. It was swelled in a reaction vessel with about 4 mL of 50% 
morpho line in dimethylformamide (DMF) for an hour. It was washed three times with DMF. A 
coupling solution of 3 molar equivalents each of Fmoc-L-Pro-OH, triethylamine (TEA), HOBt, 
and HBTU dissolved in about 4 mL DMF was added to the resin and allowed to react for 1 .5 
hours. The resin was washed three times with DMF. A Kaiser test was performed to ensure that 
the coupling reaction had gone to completion. The solution was removed by filtration and the 
resin was washed three times for five minutes each with 4 mL of 50% morpho line in DMF to 
remove the Fmoc protecting group. Another Kaiser test was performed to ensure that all of the 
protecting groups had been removed. The resin was washed with DMF three more times, then 
split equally into sixteen different reaction vessels. Separate coupling solutions containing 0.2 
molar equivalents to the initial amount of resin were made of HOBt, HBTU, TEA, and one 
Fmoc-protected amino acid dissolved in 0.75 mL of DMF. All of the standard amino acids were 
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used except tryptophan, methionine, and cysteine, as they are susceptible to oxidation, and 
proline, to ensure that the sequences that were synthesized contained only the three prolines in 
the positions desired. The coupling reaction was allowed to run overnight. The beads were 
repooled, then deprotected using morpho line washes and checked with a Kaiser test. These 
processes were repeated to produce a peptide with prolines at positions 2, 5, and 7, and 
randomized amino acids at the other positions. The total number of possible sequences 
synthesized was 164, or 6.5x104. After the synthesis of the chain was completed, the side chains 
were deprotected using a 4 rnL solution of 95% trifluoroacetic acid (TF A), 2.5% 
triisopropylsilane (TIS), and 2.5% deionized water. 
The success of the synthesis was assessed with Edman degradation. Two beads at random 
were selected to undergo sequencing. The sequence of the first bead was Arg-Pro-Glu-Gly-Pro­
Ser-Pro, and the sequence of the second bead was Val-Pro-Phe-Ser-Pro-Gly-Pro. They both 
contain proline at the 2, 5, and 7 positions and a mixture of the other amino acids used at the 
randomized positions. Therefore, the synthesis of the randomized library was determined to be a 
success, and the library was ready to be screened for binding affinity. 
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Chapter IV: ELISA Screen and Polymerization Assays 
A. ELISA Overview 
Three different methods can be used to screen for a desired property in a peptide 
combinatorial library. The first is to use a biologic peptide method, such as a phage display.34 
The second is to synthesize the library on a solid support, cleave the compounds from the resin, 
then run the screen. The third method is to synthesize the library on the resin in a one-bead one­
compound fashion, run the screen with the peptides remaining on the bead, and then select the 
beads with the desired properties to analyze. We chose to analyze the library through the third 
method to ensure easy identification of hit compounds, and used an ELISA, or enzyme-linked 
immunosorbent assay, to select for the peptides in the combinatorial library that had the highest 
binding affinity to hemoglobin. An ELISA is a simple technique where enzyme chemistry and 
immunology are linked to identify the presence of an antigen with high sensitivity.35 It is a 
common technique utilized in many laboratories. 
An ELISA can be performed as heterogeneous assays or homogenous assays. As the 
name suggests, homogenous ELISAs take place in one phase, generally solution phase. These 
assays require all of the reagents to be added simultaneously as the intermediates cannot be 
purified.36 Because ofthis, these ELlS As have reduced efficiency and are less popular. More 
often, heterogenous ELISAs are performed, which involve adhering one of the reagents, 
generally the antigen, to a solid phase. Because this solid phase can be easily separated from 
solvents, washing steps are simple; thus, reagents can be added sequentially with washing 
between each step. 
An ELISA can be utilized with a one-bead one-compound peptide library to select for the 
peptides from a combinatorial library that bind the most tightly to an antigen. A depiction of this 
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process can be seen in Figure IV.I. First, the antigen, which is deoxygenated Hb S in this 
experiment, is diluted in phosphate-buffered saline (PBS) and incubated in a plate with the 
combinatorial library, allowing it to interact with the peptides on the beads. The beads containing 
peptides that bind to the antigen more tightly will bind to a lot of the antigen, while the beads 
containing weakly-binding peptides will only bind a small amount of antigen and the beads 
containing nonbinding peptides will bind a negligible amount of the antigen. After this 
differential binding process takes places, the excess antigen is washed off and a solution of 
primary antibodies, which bind specifically to the antigen, is added. This is added in a blocking 
buffer that has detergents or other compounds that block nonspecific interactions to prevent the 
antibodies from binding with the parts of the plate instead of the antigen. After the antibodies 
bind, the excess primary antibodies are washed off, and a solution of secondary antibodies is 
added. Secondary antibodies bind specifically to the primary antibody, and are linked to an 
enzyme such as alkaline phosphatase that catalyses a colorimetric reaction. After these are bound 
and the excess is washed off, a reagent such as BCIP (5-bromo-4-chloro-3-indyl phosphate) is 
added to react with the enzyme and produce a colored product as shown in Figure IV.2 that 
precipitates on the bead,37 which allows for identification and quantification of the antigen. The 
beads that have the most tightly binding peptides interact with the highest amount of antigen and 
therefore will have the greatest color change to a deep purple. Beads that contain weakly binding 
and nonbinding peptides have a small or no color change. 
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Step One Step Two Step Three 
Step Four Step Five 
Figure IV.1 The overview of the ELISA screen with a one-bead one-compound combinatorial 
library. The antigen (Hb S) interacts with the peptides. Next, the primary antibodies are added 
and bind to the antigen. In the next step, the secondary antibodies are added and bind to the 
primary antibodies. Finally, the substrate for the conjugated enzyme is added and the enzymes 
catalyzes a colorimetric reaction. The end result is a color change where antigen is present. 
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Figure IV.2. The reaction of BCIP and NBT to produce two colored products, indigo dye and 
formazan. 
These types of ELISAs have distinct advantages as screening methods. The first is that 
they are simple and widely used. The materials needed are relatively inexpensive and safe, and 
the screening process is rapid. Millions of beads can be tested in a short amount of time.37 Also, 
the process is easily automated.38 The results can be quantified by measuring the color intensity. 
The process is sensitive, and levels of 0.0 1 to 1 J.1g/mL of antigen can be identified.36 Because of 
these advantages, peptide screening using ELISA has become a widely used tool. For example, 
ELISAs are used frequently in diagnosing bacterial and viral infections because of their high 
sensitivity and simplicity.39 Therefore, we utilized an ELISA to screen the combinatorial library 
to fmd peptides that bind tightly to sickle cell hemoglobin. 
B. ELISA Experimental 
Before the ELISA was run, a Western blot was performed to ensure that the stock 
solutions of primary and secondary antibodies were functional. Solutions of sickle cell 
hemoglobin with concentrations of 0.2 mg/mL, 0.04 mg/mL, and 0.008 mg/mL, loading buffer 
that contained 50 mM Tris-HCI, 2.5% SDS, 0.02% Bromophenol Blue, 5% (3-mercaptoethanol, 
and 1 0% glycerol, and 50 mM PBS were heated at 1 00°C for ten minutes. The. solutions were run 
36 
on a SDS polyacrylamide gel which was then stained with Gel CodeBlue. The proteins were 
transferred onto an Immobilion-P membrane. The membrane was shaken with a blocking buffer 
of 0.1 % TBST with 5% evaporated milk for 90 minutes. A primary antibody solution with a 
I :200 dilution of the goat anti-hemoglobin stock solution in blocking buffer was shaken with the 
membrane overnight at 4 ·C. The membrane was rinsed four times with 0.1 % TBST and then 
incubated for 90 minutes with a solution with a 1 :5000 dilution of the rabbit anti-goat stock 
solution in blocking buffer. The membrane was washed four times with 0. 1 % TBST and alkaline 
phosphate (AP) buffer. A solution with a 1 : 1 00 dilution ofNBTIBCIP stock solution in AP 
buffer was shaken with the membrane until color developed. The blot developed purple regions, 
showing that the hemoglobin in the solution was successfully identified with the reagents used 
and the stock solutions were functioning correctly. 
Next, the library was screened using an ELISA. All of the steps were performed in the 
anaerobic chamber to test deoxygenated hemoglobin. The library was placed in a 35 by 1 0  mm 
plate and washed thoroughly with methanol then ultrapure water to ensure purity. It was then 
shaken with blocking buffer for three hours. It was rinsed three times with PBST and one time 
with TBS. A solution was prepared of 2 mglmL of Hb S, 5 mglmL of sodium dithionite to 
deoxygenate the hemoglobin, and 0.1 % TBST. This was shaken with the resin for three hours. 
The supernatant was collected and analyzed by ultraviolet visible spectroscopy to ensure that the 
hemoglobin remained deoxygenated. The spectrum showed a single peak at 554 nm, which is 
characteristic of deoxygenated hemoglobin. The resin was then washed three times with PBST 
and once with TBS. A primary antibody solution with a 1 :200 dilution of the goat anti­
hemoglobin stock solution in blocking buffer was shaken with the resin for three hours. The 
supernatant was removed and another washing cycle was performed. A secondary antibody 
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solution with a I :5000 dilution of the rabbit anti-goat stock solution in blocking buffer was 
shaken with the resin for three hours. The resin was washed three times with PBST, once with 
TBS, and once with AP buffer. A solution with a 1 : 100 dilution ofNBTIBCIP stock solution in 
AP buffer was shaken with the resin until a purple color was visible on some of the beads. 
Finally, the colorimetric reaction was terminated with a few drops of hydrochloric acid. 
The appearance of the beads after the screen was completed can be seen in Figure IV.3. A 
gradient of colors from colorless to deep purple was seen, indicating that the screen was 
successful in separating strongly binding peptides from weakly binding and non-binding 
peptides. The beads with the peptides that bound the most strongly to the sickle cell hemoglobin 
had the strongest response to the ELISA and had the darkest color. 
Figure IV.3 The appearance of the beads after the ELISA screen. A gradient of coloration was 
seen, indicating that the screen was able to effectively distinguish tightly binding peptides from 
loosely binding or nonbinding peptides. Each bead is about 100 J.1M in diameter. 
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The beads that were colored the darkest were isolated and sequenced by Edman 
degradation. Unfortunately due to sequencing errors due to improper washing of the final bead, 
the majority of the peptides that were isolated could not be identified. However, the sequence of 
one of the peptides was obtained, Lys-Pro-Asp-Val-Pro-Phe-Pro, named LHS I .  To compare, the 
sequence of ZSF39 is Glu-Pro-Trp-Asn-Pro-Ile-Pro. While the position of the prolines are 
obviously kept constant, the other positions do not show any similarity. For example, at position 
I ,  LHS I has a positively charged lysine residue, while ZSF39 has a negatively charged glutamic 
acid residue. If these two peptides have similar mechanisms of action, it is probably due to the 
effect of the prolines on the structure of the backbone and not interactions from the other four 
positions. It is also possible that LHS I is binding to different area of hemoglobin than ZSF39 
and will either have a different mechanism of inhibiting polymerization or will not affect 
polymerization. 
C. Polymerization Assay Overview 
To determine if LHS I has any activity against polymerization, polymerization assays 
were performed. In a polymerization assay, the hemoglobin is deoxygenated with sodium 
dithionite and incubated with the peptide of interest in a high salt buffer of PBS at 30 T. The 
status of polymerization is tracked using ultraviolet visible spectroscopy. As the hemoglobin 
polymerizes, the solution becomes more turbid, causing a change in absorption. Hemoglobin 
polymerization is characterized by a delay time between deoxygenation and when polymers start 
to form. This delay time is very dependent upon concentration, and is reproducible in 
macroscopic volumes but not at very small concentrations. It has been the subject of a lot of 
study, as the ramifications could have clinical significance. This delay time is often longer than 
the transit time for a red blood cell in circulation, meaning usually hemoglobin in erythrocytes is 
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reoxygenated before polymerization can occur in the body.4o This explains why the symptoms of 
sickle cell disease only occur in patients when the deoxygenation process is exceptional, for 
example in times of exertion when more oxygen is released to the muscle cells. 
The kinetics of the delay time have been attributed to two types of nucleation, 
homogenous and heterogenous.41 When the hemoglobin is initially deoxygenated, the monomers 
randomly aggregate to form nuclei in the solution. These nuclei are not very stable and tend to 
fall apart easily. Therefore, many nuclei must form before one is stable enough to allow for 
further aggregation and the formation of polymers.9 This is known as homogenous nucleation, 
and is a fairly slow process. After homogenous nucleation has occurred and polymers have 
formed, new nuclei can form on the surface of the polymers. These nuclei are much more stable 
than the ones formed by homogeneous nucleation, so polymerization occurs more rapidly, 
leading to an exponential growth of polymers. 10 The two nucleation processes can be seen in 
Figure IV.4. 
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Figure IV.4 The two models of nucleation. In homogenous nucleation, nuclei must come 
together and form a stable aggregate in order to build a polymer. This process is slow because 
the aggregate is often unstable. In heterogenous nucleation, in comparison, nuclei grow on the 
surface of the polymers already created and are much more stable. This happens at a quicker rate 
and generates exponential polymer growth. lO 
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D. Polymerization Assays Experimental 
Polymerization assays were done on samples with hemoglobin with no peptide added as a 
control, hemoglobin with LHSI added, and hemoglobin with ZSF39 added. To run an assay, 
solutions were made of 5 mg/mL sodium dithionite and 1 .87 M PBS and incubated at 0 °C for 
ten minutes. Other solutions of 0.69 mg/mL of hemoglobin, 100 J.lM ofthe peptide, and enough 
50 mM PBS to bring the total volume to 500 mL were made and incubated at 4 °C for ten 
minutes. After incubation, the two solutions were mixed and their temperatures were raised to 30 
°C.  The absorptions of the solutions at 700 nm were measured until the maximum 
polymerization had been reached. An example of a typical polymerization curve can be seen in 
Figure IV.5. 
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Figure IV.S A typical output from a polymerization assay. As can be seen, after a 
short delay time, the hemoglobin polymerizes in an exponential fashion, causing the 
solution to become more turbid and allowing less light to be transmitted. The delay 
time can be calculated to compare the efficacy of different polymerization inhibition 
methbds. 
Polymerization assays of 100 �M of LHS l ,  ZSF39, and control solutions were performed 
simultaneously and the fold change of each delay times as compared to the control was 
calculated. The results from the polymerization assays can be seen in Tables IV. l and IV.2. 
Table IV.2 The delay times of the control solutions, LHS1  solutions, and ZSF39 solutions as 
compare d t  th t 1 0 e con ro . 
Solution Control LHSI ZSF39 
Delay Time for Trial 1 2.57 7.52 4.20 (sec) 
Delay Time for Trial 2 3.24 9.04 4.78 (sec) 
Delay Time for Trial 3 7.03 1 1 . 86 1 1 . 12 (sec) 
Mean of Delay Times 4.28 9.47 6.70 
Standard Deviation of 2.41 2.20 3 .84 Delay Times 
Table IV.2 The fold changes for the delay times of the control solutions, LHS 1 solutions, and 
Solution 
Delay Time Fold 
Change for Trial 1 
Delay Time Fold 
Change for Trial 2 
Delay Time Fold 
Change for Trial 3 
Mean of Fold 
Changes 
Standard Deviation of 
Fold Changes 
ZSF39 1 f d t th t 1 so u IOns as compare 0 e con ro . 
Control LHSI 
1 2.92 
1 2 .80 
1 1 .70 
1 2.47 
0.00 0.67 
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ZSF39 
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1 .48 
1 .60 
1 .57 
0.08 
3.5 � 
£ 
.s 3 
"0 � r.. 2.5 co 0- I · ' -' Q,. 
e 
0 _ u 0 2 
� l:: co = 
I � 0 r-� u  1.5 
co .::: u 
"0 1 ,.. - '---, -
0 '-
= 0.5 co � 
::;: 
0 
Control LHSl ZSF39 
Solutions 
Figure IV.6 The mean fold changes for the delay times as compared to the control for the 
control solutions, the solutions with LHS l ,  and the solutions with ZSF39, with error bars 
corresponding to the standard deviation. 
Conclusions and Future Work 
These exciting results show that LHS 1 is a peptide that shows promise in inhibiting sickle 
cell hemoglobin polymerization. It is able to extend the delay time significantly longer than both 
Hb S without a peptide ligand and Hb S with ZSF39. This result opens up many avenues for 
future exploration. One factor to explore is whether LHS 1 and ZSF39 are interacting with 
hemoglobin in the same area of the protein, or if they have different mechanisms of affecting 
polymerization. Because they have a similar backbone structure but the other four positions are 
very different between the two peptides, a possible hypothesis would be that the secondary 
structure allows it to interact with Hb S in a particular fashion and that the other four residues of 
LHS I were optimized for higher affmity to Hb S than ZSF39.  It would be insightful to take other 
routes, such as better preparation of the samples before sequencing, to determine the structure of 
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the other peptides identified from the screen and see if any similarities are present between them 
and LHS I ,  and what types of residues contribute to a larger effect on polymerization delay times. 
Another interesting direction would be to establish where the peptides are interacting with the 
hemoglobin. To have an inhibitory effect on polymerization, the peptides could either be 
interacting with the oxygenated form of Hb S in a stabilizing manner or with the deoxygenated 
form in a way that blocks polymerization. Because the peptides were both identified from 
deoxygenated screens, the mechanism of inhibition is probably with the deoxygenated form. 
Therefore, the peptides are most likely either interacting with the hydrophobic pocket or the 
mutated valine and directly blocking their interaction, or interacting with another portion of 
deoxygenated sickle cell hemoglobin and causing a slight conformational change that inhibits 
polymerization. Future work in this area should be conducted to elucidate the nature of the 
structure-function relationship of this peptide and how it can be further optimized to understand 
how it is functioning and how it can be made better. 
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